diagnost tool
price close busi may
market leader non-invas blood-
base prenat test enter larg liquid
biopsi cancer organ transplant test market
under-valued cancer test compani
trade multipl nipt compani buy
deliv strong though broader updat flurri traction
made recent week investor eagerli await acog decis
pdufa date hope around june juli track
ahead schedul matter control underappreci
manag team execut high level impress rapid traction
oncolog pharma partner oncolog assay develop oncolog
data public regulatori advanc fda breakthrough devic approv
signatera transplant draft lcd core nipt busi volum
grew one fastest quarter growth compani histori
remain meaning under-valued reiter buy rais pt
colon cancer test advanc given sensit specif data colon
caner stage patient recurr monitor publish jama oncolog
pursu medicar coverag good pre-sub meet moldx
recent launch prospect trial expect medicar coverag
expect launch signatera colon other self-pay basi
cancer data mount point see step-funct increas
stock multipl addit colon data breast cancer data
sensit specif publish clinic cancer research bladder
cancer sensit specif publish journal clinic oncolog
build landmark data lung cancer sensit specif
plan launch signatera huge billion cancer monitor market
address import unmet need determin cancer relaps american
cancer survivor year ahead imag therapeut monitor
like see data assert customized-to-the-pati
liquid biopsi typic track addit mutat lead panel
thu test may detect relaps anoth panel might miss indic
signatera liquid biopsi test detect circul tumor dna ctdna variant
allel frequenc vaf cell-fre dna provid deep depth
coverag expect addit studi demonstr signatera util come
acog get new bulletin acog annual meet expect
updat guidelin around mid-year week away meanwhil chip
away iceberg medicaid payor reimburs averag risk nipt
discuss aet other addit blue plan
drove organ revenu growth cog improv advanc
rev y/i organ back payment
last year beat midpoint pre-announc
impress sinc captur appeal revenu prior period
may go forward volum y/i q/q beat
mark one fastest quarter compani histori eas concern
around competit view gm beat strip
payment last year expand y/i reiter guid
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
rais pt even move higher last friday trade
revenu estim today close price materi
sector averag revenu multipl pt formerli appli
formerli multipl revenu estim formerli
discount back two year discount rate dilut share outstand
bake compani recent secondari offer includ proce
recent secondari offer hold cash later year also may
obtain payment partner bgi could take pro-forma cash balanc
guid reiter revenu guid y/i
manag said expect improv reimburs average-
risk nipt seen evid recent medicaid win thu derisk
guid extent howev think high end guid like
predic compani get acog decis around middl year
june juli said consensu estim present look
midpoint guidanc think setup look ok
think acog decis juli would mark upsid our/street revenu
estim mention stock price
step-funct increas pharma revenu build confid reiter
goal obtain contract valu pharma
increas vs cumul contract valu driven rise
pharma interest signatera ruo test minim residu diseas mrd
strong expect revis acog bulletin support
average-risk nipt hope mid-year price and/
aet cover average-risk nipt post acog launch signatera liquid biopsi
cancer patient partnership ex-pharma partnership
pharma plan final lcd medicar kidney test launch like end
launch panorama nipt test generead
signatera launch signatera assay test cancer cancer
patient initi lung breast colon bladder cancer top
data resid may charg cogs/test test
self-pay basi build evid reimburs if/when obtain
reimburs signatera see path reimburs
cost good sold less would nice accret
compani gross margin
model rais rev
rev model assum
oncolog revenu ruo signatera clinic test
combin respect model continu assum
zero kidney transplant test though given compani rise traction
view estim conserv
million bgi deal earlier year announc deal bgi
genom call indic expect net cash up-front
bgi deal manag treat cash payment
plan recogn futur work revenu agreement
bgi pay million up-front licens fee prepaid royalti
also receiv on-going royalti payment manag indic
call expect sum ten million dollar time think
unreason given million peopl china live cancer
number american live cancer accord
prepay bgi genom sequenc servic reagent relat
partnership ntra signatera mrd minim residu diseas molecular
monitor test offer china first specialti hospit network without
need cfda approv broadli follow like cfda regulatori approv
signatera mrd bgi dnbseq instrument platform indic call
cfda approv burdensom process suggest bgi may
commerci signatera test china believ investor treat
entir opportun free call option opportun bake
buy unchang target price may
diagnost tool
either multipl stock forward year sell-sid consensu revenu
estim
bgi enabl offer huge import china market bgi provid
highli respect partner larg china market further global
expans goal use import supplier chang
exist suppli agreement held posit sequenc
agnost decentr test enabl peopl world run test sampl
local site sequenc vs send sampl ntra lab ca
done partnership one think remind
investor deal announc around time last year strictli
relat pre-nat test thu think done announc addit
strateg deal believ would logic want access
compel oncolog test menu even see partnership outsid bgi
recal work thermo fisher subsidiari alreadi one lambda
transplant market thu rule possibl sign deal
thermo use ion torrent sequenc perhap access part
world mayb may commerci strength
acog expect steadi improv average-risk nipt reimburs
provid timet acog decis spoke
manag topic call sens support build
nice consortium nipt compani tri build support
new acog bulletin indic call new guidanc way
support averag risk nipt still wait acog publish
new bulletin remain activ engag aet think
coverag polici decis inevit get paid time
average-risk nipt volum think reason could get paid roughli
time least end view expect payor
outsid aet come well time
step-funct increas pharma revenu build confid target
contract valu pharma increas vs
cumul contract valu driven pharma interest
signatera ruo test minim residu diseas mrd molecular monitor
natera indic contract valu convert revenu cours
month thu expect modest contribut oncolog
revenu pick beyond studi trial
pharma compani includ pharma lead io compani
studi trial cancer indic lung
breast colon prostat pan-canc applic one notabl exampl bm
use help determin patient receiv chemo alon chemo
opdivo expect mani deal come meaning econom
entri kidney transplant diagnost complet analyt
valid clinic valid held pre-submiss meet obtain draft local
coverag decis lcd prospera kidney transplant assay complet clia
valid obtain z-code hope launch kidney test end
final medicar coverag think possibl launch
obtain final medicar coverag decis end ahead
prior expect dont expect meaning revenu kidney
even model zero primarili use conserv
buy unchang target price may
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price may
diagnost tool
buy unchang target price may
diagnost tool
buy unchang target price may
diagnost tool
